AstraZeneca Pharma India posts Q2 PAT at Rs. 38.43 Cr
We are witnessing a steady and sustainable growth in the country as the Q2 revenue from operations increased by 31%
We are witnessing a steady and sustainable growth in the country as the Q2 revenue from operations increased by 31%
In Q2 FY25, our crop protection segment reported revenue of Rs. 159 crore, with an EBIT margin of 5%
Hospital business revenues increase 13.9% to Rs. 1,655 crore
Medanta is expected to incur a project capex of ~Rs. 600 crores in next 3-4 years
The group plans to establish new hospitals in Kerala developing large health cities in Kochi and Kozhikode
The INTerpath-009 clinical trial demonstrates continued expansion of the INTerpath clinical program
Silica is a proven and highly effective anti-caking agent that has been used for decades
Company receives acceptability, in principle, for ZyVac TCV making it eligible for purchase by United Nations procurement agencies
This partnership will enable healthcare organizations to provide best-in-class patient/consumer experiences
Subscribe To Our Newsletter & Stay Updated